Showing results (391-400 of 1,074) with videos related to
Sort By:
Pageof 108
Therapeutic Advances in Neurological Disorders|December 14, 2011
Natural toxins implicated in the development of Parkinson's diseaseMohamed Salama, Oscar Arias-CarriónTherapeutic Advances in Neurological Disorders|January 26, 2012
Treatment de-escalation after mitoxantrone therapy: results of a phase IV, multicentre, open-label, randomized study of subcutaneous interferon beta-1a in patients with relapsing multiple sclerosisPeter Rieckmann, Fedor Heidenreich, Michael Sailer, et al.Therapeutic Advances in Neurological Disorders|January 26, 2012
Smoking: effects on multiple sclerosis susceptibility and disease progressionDean M WingerchukTherapeutic Advances in Neurological Disorders|October 20, 2011
The interferon beta therapies for treatment of relapsing-remitting multiple sclerosis: are they equally efficacious? A comparative review of open-label studies evaluating the efficacy, safety, or dosing of different interferon beta formulations alone or in combinationVolker Limmroth, Norman Putzki, Norman J KachuckTherapeutic Advances in Neurological Disorders|May 17, 2012
Erythropoietin: still on the neuroprotection roadNelvys Subirós, Diana García Del Barco, Rosa M Coro-AntichTherapeutic Advances in Neurological Disorders|August 11, 2018
Inflammatory molecules might become both biomarkers and therapeutic targets for stroke managementLaura Ramiro, Alba Simats, Teresa García-Berrocoso, et al.Therapeutic Advances in Neurological Disorders|November 6, 2009
The potential for estrogens in preventing Alzheimer's disease and vascular dementiaJames W Simpkins, Evelyn Perez, Xiaofei Wang, et al.Therapeutic Advances in Neurological Disorders|October 25, 2014
Extended interval dosing of natalizumab: a two-center, 7-year experienceRoberto Bomprezzi, Siddharama PawateTherapeutic Advances in Neurological Disorders|October 25, 2014
Fumarate treatment in progressive forms of multiple sclerosis: first results of a single-center observational studyKatrin Strassburger-Krogias, Gisa Ellrichmann, Christos Krogias, et al.Therapeutic Advances in Neurological Disorders|September 2, 2017
The role of natalizumab in the treatment of multiple sclerosis: benefits and risksBarry A SingerPageof 108